Complete the form to be included in our online directory to help connect patients and referring physicians with healthcare professionals experienced in managing patients with ATTR.
After registering, your information will be evaluated and verified before potential addition to the directory.
Filling out the registration form does not guarantee inclusion in the ATTR Physician Directory.
Click here to remove yourself from this directory or here to update your information.
*Indicates required field.
You are now leaving amvuttra.com.
You are now being directed to another Alnylam website.
Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
The diagnostic algorithm should always begin with a monoclonal protein screen to assess for
AL amyloidosis. If AL amyloidosis is suspected, initiate laboratory testing to assess
for monoclonal protein production and evidence of vital organ involvement or
dysfunction. In AL amyloidosis, free lambda or free
kappa levels are elevated.